–– Topline Results From ENLIGHTEN-2 Study Expected in Q4 2018 –– DUBLIN, April 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced completion of patient enrollment in ENLIGHTEN-2, the second of two key phase 3 studies in the ENLIGHTEN clinical development program for...
from PR Newswire: //https://ift.tt/2Jtoyww
No comments:
Post a Comment